2022-RA-170-ESGO Comparison of the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate on fertility-preserving treatment in patients with atypical endometrial hyperplasia: a prospective, open-label, randomized controlled phaseIIstudy

Xu, Zhiying; Yang, Bingyi; Shan, Weiwei; Liao, Jiongbo; Shao, Wenyu; Wu, Pengfei; Zhou, Shuang; Ning, Chengcheng; Luo, Xuezhen; Zhu, Qin; Zhang, Hongwei; Ma, Fenghua; Guan, Jun; Chen, Xiaojun

doi:10.1136/ijgc-2022-esgo.199

Search citation statements

Order By: Relevance

Paper Sections

Select...

Miscellaneous1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2022

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Zhiying Xu presented the results of a single-center, phase II, open-label, randomized controlled trial assessing the effect of levonorgestrel-intrauterine system with or without oral megestrol acetate versus megestrol acetate alone on fertility preserving treatment in patients with atypical endometrial hyperplasia 35. A total of 132 patients were randomly assigned to (1:1:1) megestrol acetate, levonorgestrel-intrauterine system, and levonorgestrel-intrauterine system with megestrol acetate.…”

Section: Miscellaneousmentioning

confidence: 99%

Best original research presented at the 23rd European Congress on Gynaecological Oncology—Best of ESGO 2022

Kacperczyk‐Bartnik

Bizzarri

Ángeles

et al. 2022

Int J Gynecol Cancer

View full text Add to dashboard Cite

Best of ESGO 2022 includes a selection of best original research presented during the 23rd European Congress on Gynaecological Oncology between October 27 and 30, 2022 in Berlin. Out of 1107 submitted abstracts, authors of studies which obtained the highest scores in a blinded review process were invited to present their results during four oral sessions, young investigators session, and oral poster sessions. By means of this publication, we aim to provide readers with an overview of the best quality research presented at the European Society of Gynaecological Oncology (ESGO) 2022.

show abstract

Section: Miscellaneousmentioning

confidence: 99%